pharmaceutical-investing Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options